These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

120 related articles for article (PubMed ID: 38095888)

  • 1. Spending on Dual Over-the-Counter and Prescription Drugs in the Medicare Part D Program.
    Socal MP; Wang Y; Plummer E; Anderson GF; Bai G
    JAMA; 2024 Jan; 331(1):72-75. PubMed ID: 38095888
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Why France Spends Less Than the United States on Drugs: A Comparative Study of Drug Pricing and Pricing Regulation.
    Raimond VC; Feldman WB; Rome BN; Kesselheim AS
    Milbank Q; 2021 Mar; 99(1):240-272. PubMed ID: 33751664
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Analysis of Proposed Medicare Part B to Part D Shift With Associated Changes in Total Spending and Patient Cost-Sharing for Prescription Drugs.
    Hwang TJ; Jain N; Lauffenburger JC; Vokinger KN; Kesselheim AS
    JAMA Intern Med; 2019 Mar; 179(3):374-380. PubMed ID: 30640379
    [TBL] [Abstract][Full Text] [Related]  

  • 4. The Effect of Medicare Part D on Prescription Drug Spending and Health Care Use: 6 Years of Follow-up, 2007-2012.
    Park T; Jung J
    J Manag Care Spec Pharm; 2017 Jan; 23(1):5-12. PubMed ID: 28025927
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Patient and Payer Incentives to Use Patented Brand-Name Drugs vs Authorized Generic Drugs in Medicare Part D.
    Dusetzina SB; Sarpatwari A; Carrier MA; Hansen RA; Keating NL; Huskamp HA
    JAMA Intern Med; 2021 Dec; 181(12):1605-1611. PubMed ID: 34661600
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Recommendations for Lowering Prescription Drug Spending in Public Programs.
    Jazowski SA; Dusetzina SB
    Ann Intern Med; 2019 Dec; 171(11):855-856. PubMed ID: 31711129
    [No Abstract]   [Full Text] [Related]  

  • 7. Sources of regional variation in Medicare Part D drug spending.
    Donohue JM; Morden NE; Gellad WF; Bynum JP; Zhou W; Hanlon JT; Skinner J
    N Engl J Med; 2012 Feb; 366(6):530-8. PubMed ID: 22316446
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Effects of Medicare Part D on drug affordability and use: Are seniors with prior high out-of-pocket drug spending affected more?
    Mott DA; Thorpe JM; Thorpe CT; Kreling DH; Gadkari AS
    Res Social Adm Pharm; 2010 Jun; 6(2):90-9. PubMed ID: 20511108
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Variation in Prescription Drug Coverage Enrollment Among Vulnerable Beneficiaries With Glaucoma Before and After the Implementation of Medicare Part D.
    Blumberg DM; Prager AJ; Liebmann JM
    JAMA Ophthalmol; 2016 Feb; 134(2):212-20. PubMed ID: 26720853
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Role of Specialty Drugs in Rising Drug Prices for Medicare Part D.
    Hayford TB
    JAMA Health Forum; 2024 May; 5(5):e241188. PubMed ID: 38787543
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Prescription Drug Spending in Fee-for-Service Medicare, 2008-2019.
    Dusetzina SB; Huskamp HA; Qin X; Keating NL
    JAMA; 2022 Oct; 328(15):1515-1522. PubMed ID: 36255428
    [TBL] [Abstract][Full Text] [Related]  

  • 12. The relationship between the number of available therapeutic options and government payer (medicare part D) spending on topical drug products.
    Kwa MC; Tegtmeyer K; Welty LJ; Raney SG; Luke MC; Xu S; Kong B
    Arch Dermatol Res; 2020 Oct; 312(8):559-565. PubMed ID: 32055932
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Regional variation in Medicare Part D drug spending.
    Mukherjee D; Mukherjee C
    N Engl J Med; 2012 May; 366(19):1842; author reply 1842-3. PubMed ID: 22571214
    [No Abstract]   [Full Text] [Related]  

  • 14. Regional variation in Medicare Part D drug spending.
    Flansbaum B
    N Engl J Med; 2012 May; 366(19):1842; author reply 1842-3. PubMed ID: 22571215
    [No Abstract]   [Full Text] [Related]  

  • 15. Association of Prescription Drug Price Rebates in Medicare Part D With Patient Out-of-Pocket and Federal Spending.
    Dusetzina SB; Conti RM; Yu NL; Bach PB
    JAMA Intern Med; 2017 Aug; 177(8):1185-1188. PubMed ID: 28558108
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Impacts of generic competition and benefit management practices on spending for prescription drugs: evidence from Medicare's Part D benefit.
    Sheingold S; Nguyen NX
    Medicare Medicaid Res Rev; 2014; 4(1):. PubMed ID: 24918023
    [TBL] [Abstract][Full Text] [Related]  

  • 17. The effect of Medicare Part D on drug and medical spending.
    Zhang Y; Donohue JM; Lave JR; O'Donnell G; Newhouse JP
    N Engl J Med; 2009 Jul; 361(1):52-61. PubMed ID: 19571283
    [TBL] [Abstract][Full Text] [Related]  

  • 18. A comparison of costs of Medicare Part D prescriptions dispensed at retail and mail order pharmacies.
    Carroll NV
    J Manag Care Spec Pharm; 2014 Sep; 20(9):959-67. PubMed ID: 25166295
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Prescription Drugs-List Price, Net Price, and the Rebate Caught in the Middle.
    Dusetzina SB; Bach PB
    JAMA; 2019 Apr; 321(16):1563-1564. PubMed ID: 30840047
    [No Abstract]   [Full Text] [Related]  

  • 20. Medicare Part D: Patients Bear The Cost Of 'Me Too' Brand-Name Drugs.
    Gastala NM; Wingrove P; Gaglioti A; Petterson S; Bazemore A
    Health Aff (Millwood); 2016 Jul; 35(7):1237-40. PubMed ID: 27385239
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 6.